Annexon reports first quarter 2024 financial results and key anticipated milestones

Multiple value-creating catalysts across the annexon portfolio throughout 2024 pivotal phase 3 data for anx005 in guillain-barrÉ syndrome (gbs) expected in second quarter 2024; potential to be the first targeted treatment for gbs new phase 2 data showing neuroprotection of vision and vision-associated structures by anx007 in geographic atrophy (ga) presented at arvo 2024; initiation of pivotal phase 3 anx007 archer ii trial in ga expected in mid-2024 clinical proof of concept (poc) data for anx1502, an oral classical pathway inhibitor for chronic autoimmune conditions, on track for second half of 2024 robust balance sheet with cash, cash equivalents, and short-term investments of approximately $264.9 million as of march 31, 2024, and anticipated runway into mid-2026 brisbane, calif., may 13, 2024 (globe newswire) -- annexon, inc. (nasdaq: annx), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today highlighted portfolio progress and reported first quarter 2024 financial results.
ANNX Ratings Summary
ANNX Quant Ranking